These top-line results ought to boost Brilinta’s sales, which have been disappointing to date; however, the magnitude of the boost will depend a lot on the actual risk reduction observed in this trial, which wasn't disclosed today. Moreover, generic Plavix remains an obstacle to commercial uptake.